GLABF (Gemina Laboratories) Effective Interest Rate on Debt %: -2.30% (As of Oct. 2025)


What is Gemina Laboratories Effective Interest Rate on Debt %?

Gemina Laboratories GLABF -27.59% Effective Interest Rate on Debt % is -2.30% as of Oct. 2025. The stock has 2 warning signs investors should review.

Effective Interest Rate on Debt % is the usage rate that a borrower actually pays on a debt. It is calculated as the positive value of Interest Expense divided by its average total debt. Total debt equals to Long-Term Debt & Capital Lease Obligation plus Short-Term Debt & Capital Lease Obligation. Gemina Laboratories's annualized positive value of Interest Expense for the quarter that ended in Oct. 2025 was $-0.00 Mil. Gemina Laboratories's average total debt for the quarter that ended in Oct. 2025 was $0.17 Mil. Therefore, Gemina Laboratories's annualized Effective Interest Rate on Debt % for the quarter that ended in Oct. 2025 was -2.30%.

Gemina Laboratories  (OTCPK:GLABF) Effective Interest Rate on Debt % Explanation

Effective Interest Rate on Debt % measures the usage rate that a borrower actually pays on a debt.

Gemina Laboratories Effective Interest Rate on Debt % Related Terms

Gemina Laboratories Effective Interest Rate on Debt % Historical Data

* Premium members only.

The historical data trend for Gemina Laboratories's Effective Interest Rate on Debt % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Gemina Laboratories Effective Interest Rate on Debt % Chart

Gemina Laboratories Annual Data
Trend Jan21 Jan22 Jan23 Jan24 Jan25
Effective Interest Rate on Debt %
0.00 1.75 0.00 5.18 18.30

Gemina Laboratories Quarterly Data
Jan21 Apr21 Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23 Jan24 Apr24 Jul24 Oct24 Jan25 Apr25 Jul25 Oct25
Effective Interest Rate on Debt % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 12.89 11.93 21.89 -2.28 -2.30

GLABF vs VRTX, REGN, ALNY: Effective Interest Rate on Debt % Comparison

For the Biotechnology subindustry, Gemina Laboratories's Effective Interest Rate on Debt %, along with its competitors' market caps and Effective Interest Rate on Debt % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Gemina Laboratories Effective Interest Rate on Debt % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Gemina Laboratories's Effective Interest Rate on Debt % distribution charts can be found below:

* The bar in red indicates where Gemina Laboratories's Effective Interest Rate on Debt % falls into.


Gemina Laboratories Effective Interest Rate on Debt % Calculation

Gemina Laboratories's annualized Effective Interest Rate on Debt % for the fiscal year that ended in Jan. 2025 is calculated as

Effective Interest Rate on Debt %
=-1  *  Interest Expense/( (Total Debt  (A: Jan. 2024 )+Total Debt  (A: Jan. 2025 ))/ count )
=-1  *  -0.114/( (0.361+0.885)/ 2 )
=-1  *  -0.114/0.623
=18.30 %

where

Total Debt  (A: Jan. 2024 )
=Long-Term Debt & Capital Lease Obligation + Short-Term Debt & Capital Lease Obligation
=0.153 + 0.208
=0.361

Total Debt  (A: Jan. 2025 )
=Long-Term Debt & Capital Lease Obligation + Short-Term Debt & Capital Lease Obligation
=0.122 + 0.763
=0.885

Gemina Laboratories's annualized Effective Interest Rate on Debt % for the quarter that ended in Oct. 2025 is calculated as

Effective Interest Rate on Debt %
=-1  *  Interest Expense/( (Total Debt  (Q: Jul. 2025 )+Total Debt  (Q: Oct. 2025 ))/ count )
=-1  *  0.004/( (0.176+0.172)/ 2 )
=-1  *  0.004/0.174
=-2.30 %

where

Total Debt  (Q: Jul. 2025 )
=Long-Term Debt & Capital Lease Obligation + Short-Term Debt & Capital Lease Obligation
=0 + 0.176
=0.176

Total Debt  (Q: Oct. 2025 )
=Long-Term Debt & Capital Lease Obligation + Short-Term Debt & Capital Lease Obligation
=0 + 0.172
=0.172

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Effective Interest Rate on Debt %, the Interest Expense of the last fiscal year and the average total debt over the fiscal year are used. In calculating the quarterly data, the Interest Expense data used here is four times the quarterly (Oct. 2025) interest expense data. Effective Interest Rate on Debt % is displayed in the 30-year financial page.

What does a Effective Interest Rate on Debt % of -2.30% mean?
Gemina Laboratories (GLABF) has a Effective Interest Rate on Debt % of -2.30% as of Oct. 2025. Effective interest rate on debt is the rate a company actually pays on its debt. View historical data on Gemina Laboratories and its competitors.
Is Gemina Laboratories' Effective Interest Rate on Debt % too high?
Gemina Laboratories' current Effective Interest Rate on Debt % is -2.30%.
How does Gemina Laboratories' Effective Interest Rate on Debt % compare to VRTX and REGN?
Gemina Laboratories' Effective Interest Rate on Debt % of -2.30% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Effective Interest Rate on Debt % for a Biotechnology company?
A good Effective Interest Rate on Debt % depends on the Biotechnology industry context. However, Effective Interest Rate on Debt % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Effective Interest Rate on Debt % mean?
A high Effective Interest Rate on Debt % can signal that a stock is expensive relative to its fundamentals. Effective interest rate on debt is the rate a company actually pays on its debt. View historical data on Gemina Laboratories and its competitors. Gemina Laboratories's current Effective Interest Rate on Debt % is -2.30%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Gemina Laboratories stock overvalued right now?
Gemina Laboratories (GLABF) has a current Effective Interest Rate on Debt % of -2.30%. The current Effective Interest Rate on Debt % is -2.30%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Effective Interest Rate on Debt % calculated?
Effective Interest Rate on Debt % is calculated from a company's financial statements. For Gemina Laboratories (GLABF), the current Effective Interest Rate on Debt % is -2.30% as of Oct. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Gemina Laboratories Business Description

Address 3600 Gilmore Mall, Suite 302, Burnaby, BC, CAN, V5G 4R8
Gemina Laboratories Ltd is a biotechnology company that operates in the In Vitro Diagnostics (IVD) and human wellness monitoring market under the name Gemina Labs. The company endeavors to develop novel surface functionalization chemistries for the detection of pathogens and biomarkers.